Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to 11.34%.

  • Verrica Pharmaceuticals' EBITDA Margin rose 11738400.0% to 11.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 53.21%, marking a year-over-year increase of 5663000.0%. This contributed to the annual value of 871.25% for FY2024, which is 4362200.0% up from last year.
  • According to the latest figures from Q3 2025, Verrica Pharmaceuticals' EBITDA Margin is 11.34%, which was up 11738400.0% from 11.89% recorded in Q2 2025.
  • In the past 5 years, Verrica Pharmaceuticals' EBITDA Margin registered a high of 11.89% during Q2 2025, and its lowest value of 17808.11% during Q1 2023.
  • Moreover, its 5-year median value for EBITDA Margin was 1006.38% (2023), whereas its average is 2926.24%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by -158352500bps in 2023, then skyrocketed by 173219900bps in 2024.
  • Verrica Pharmaceuticals' EBITDA Margin (Quarter) stood at 7.78% in 2021, then tumbled by -111432bps to 8680.88% in 2022, then surged by 86bps to 1238.13% in 2023, then crashed by -168bps to 3316.86% in 2024, then surged by 100bps to 11.34% in 2025.
  • Its EBITDA Margin was 11.34% in Q3 2025, compared to 11.89% in Q2 2025 and 236.41% in Q1 2025.